“…Clozapine is utilized for the management of treatment-resistant schizophrenia but is rarely utilized in children and adolescents, particularly as it is only licensed for use in patients aged 16 years and over [ 14 ], rendering its use in younger children unlicensed. Other potential reasons for clozapine’s limited utilization may relate to the low incidence of schizophrenia in younger adolescents, serious adverse effects such as neutropenia (albeit rare), and the requirement for frequent venepuncture (at least weekly for 18 weeks) [ 15 ]. Additionally, current evidence suggests that children are potentially more likely to be more sensitive to the neutropenic effects of clozapine, particularly if they are of male gender [ 16 ].…”